Filing Details

Accession Number:
0001209191-17-006404
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-01-31 16:49:32
Reporting Period:
2017-01-31
Filing Date:
2017-01-31
Accepted Time:
2017-01-31 16:49:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1370053 Anaptysbio Inc ANAB Pharmaceutical Preparations (2834) 203828755
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1639935 Nicholas Lydon C/o Anaptysbio, Inc.
10421 Pacific Center Court, Suite 200
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-01-31 203,625 $0.00 270,957 No 4 C Direct
Common Stock Acquisiton 2017-01-31 16,666 $15.00 287,623 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2017-01-31 80,877 $0.00 80,877 $0.00
Common Stock Series C Preferred Stock Disposition 2017-01-31 55,403 $0.00 55,403 $0.00
Common Stock Series D Preferred Stock Disposition 2017-01-31 67,345 $0.00 67,345 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.